J&J trial links anemia drug to patient deaths in stroke trial

09/18/2008 | Google

Preliminary results of a study on Eprex -- an anemia drug developed by Johnson & Johnson's Ortho Biotech unit and sold as Procrit in the U.S. -- showed that more ischemic stroke patients who received the drug died compared with those who received a placebo, the company announced Wednesday. Ortho Biotech said it has notified U.S. and European regulators and is undertaking further analyses of the results.

View Full Article in:

Google

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC